Kalaris Therapeutics (KLRS) Competitors $2.69 +0.01 (+0.37%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsTrendsBuy This Stock KLRS vs. OGI, EPRX, TVGN, CTMX, ENGN, CYBN, KYTX, IPHA, SXTC, and GALTShould you be buying Kalaris Therapeutics stock or one of its competitors? The main competitors of Kalaris Therapeutics include Organigram Global (OGI), Eupraxia Pharmaceuticals (EPRX), Semper Paratus Acquisition (TVGN), CytomX Therapeutics (CTMX), enGene (ENGN), Cybin (CYBN), Kyverna Therapeutics (KYTX), Innate Pharma (IPHA), China SXT Pharmaceuticals (SXTC), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. Kalaris Therapeutics vs. Its Competitors Organigram Global Eupraxia Pharmaceuticals Semper Paratus Acquisition CytomX Therapeutics enGene Cybin Kyverna Therapeutics Innate Pharma China SXT Pharmaceuticals Galectin Therapeutics Organigram Global (NASDAQ:OGI) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability. Which has more risk & volatility, OGI or KLRS? Organigram Global has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Does the media prefer OGI or KLRS? In the previous week, Organigram Global had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 1 mentions for Organigram Global and 0 mentions for Kalaris Therapeutics. Organigram Global's average media sentiment score of 0.59 beat Kalaris Therapeutics' score of 0.00 indicating that Organigram Global is being referred to more favorably in the media. Company Overall Sentiment Organigram Global Positive Kalaris Therapeutics Neutral Do insiders & institutionals have more ownership in OGI or KLRS? 34.6% of Organigram Global shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 0.1% of Organigram Global shares are held by insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is OGI or KLRS more profitable? Organigram Global has a net margin of 8.05% compared to Kalaris Therapeutics' net margin of 0.00%. Organigram Global's return on equity of -5.93% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organigram Global8.05% -5.93% -4.39% Kalaris Therapeutics N/A -62.08%-54.69% Do analysts recommend OGI or KLRS? Kalaris Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 11.52%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than Organigram Global.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram Global 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kalaris Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation & earnings, OGI or KLRS? Organigram Global has higher revenue and earnings than Kalaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganigram Global$117.47M1.52-$33.39M$0.1013.30Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A SummaryOrganigram Global beats Kalaris Therapeutics on 8 of the 12 factors compared between the two stocks. Get Kalaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLRS vs. The Competition Export to ExcelMetricKalaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.12M$3.00B$5.47B$9.53BDividend YieldN/A2.43%4.74%4.08%P/E RatioN/A17.6228.6723.80Price / SalesN/A268.97422.2688.08Price / CashN/A41.9535.4557.96Price / Book0.128.508.275.55Net Income-$58.77M-$55.06M$3.24B$259.03M7 Day Performance-2.54%-3.98%-3.63%-4.56%1 Month Performance5.08%9.59%4.40%4.49%1 Year PerformanceN/A6.72%25.97%18.05% Kalaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLRSKalaris TherapeuticsN/A$2.69+0.4%$3.00+11.5%N/A$50.12MN/A0.00110OGIOrganigram Global1.144 of 5 stars$1.53+1.3%N/A-15.3%$204.93M$117.47M15.30860News CoverageEPRXEupraxia Pharmaceuticals2.5434 of 5 stars$5.49-0.9%$11.00+100.4%+85.5%$197.40MN/A-7.2229Upcoming EarningsHigh Trading VolumeTVGNSemper Paratus Acquisition2.9693 of 5 stars$1.06-0.9%$10.00+843.4%+61.5%$194.93MN/A0.003News CoverageUpcoming EarningsShort Interest ↑CTMXCytomX Therapeutics3.9953 of 5 stars$2.40+0.4%$5.33+122.2%+75.4%$193.49M$138.10M5.00170News CoverageUpcoming EarningsAnalyst ForecastENGNenGene3.4559 of 5 stars$3.70+0.3%$23.29+529.3%-56.5%$189.09MN/A-2.2431CYBNCybin2.7265 of 5 stars$7.99-0.6%$85.00+963.8%N/A$188.48MN/A-1.8250KYTXKyverna Therapeutics2.8584 of 5 stars$4.33+2.1%$18.50+327.3%-56.2%$187.14M$7.03M-1.2896Positive NewsIPHAInnate Pharma2.3444 of 5 stars$2.04+0.5%$11.00+439.2%-1.4%$187.13M$21.77M0.00220Gap DownSXTCChina SXT Pharmaceuticals0.4878 of 5 stars$1.59-1.9%N/A-80.3%$184.48M$1.93M0.0090Analyst UpgradeGALTGalectin Therapeutics2.5126 of 5 stars$2.91-1.0%$6.00+106.2%+63.3%$184.18MN/A-4.049Positive News Related Companies and Tools Related Companies OGI Competitors EPRX Competitors TVGN Competitors CTMX Competitors ENGN Competitors CYBN Competitors KYTX Competitors IPHA Competitors SXTC Competitors GALT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLRS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
